Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin
June 27, 2025Research and Development Dermatology, Galderma, chronic pruritus of unknown origin, clinical trials, dermatological conditions, dermatology, nemolizumab, systemic sclerosis
Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, nemolizumab, in two conditions: systemic …
STENTiT treats first patient with regenerative stent for limb preservation
June 27, 2025Research and Development Cardiology, Medical University of Graz, STENTiT, chronic limb-threatening ischemia, clinical trial, limb amputation, peripheral artery disease, regenerative stent, resorbable fibrillated scaffold
STENTiT has announced the successful first patient implantation of its resorbable fibrillated scaffold (RFS), a new regenerative stent, as part …
Inizio Evoke appoints Kelly Cusumano to drive strategic growth and innovation
June 27, 2025Business Services, Marketing Consultancies, Medical Communications Corporate, Evoke Comms, Inizio Evoke, business strategist, executive vice president, marketing and communications
Inizio Evoke, a global health marketing and communications platform, has appointed Kelly Cusumano as executive vice president, growth and client …
Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases
June 27, 2025Mergers and Acquisitions, Research and Development Cardiology, Lexeo Therapeutics, PXV Funds, RNA-based therapies, cardiac genetic medicine, venBio Partners
Lexeo Therapeutics has announced a strategic partnership with life sciences investors Perceptive Xontogeny Venture Funds (PXV Funds) and venBio Partners …
Unlocking the gateway to ‘precision’ UK market access
June 27, 2025Business Services, Market Access, Market Access Consultancy, Sales and Marketing NHS, Visions4Health
As the UK healthcare system navigates a period of significant change, the path to successful market access is becoming increasingly …
PMGroup/Visions4Health unveil Excellence in Healthcare Partnerships Awards
June 26, 2025Medical Communications CHASE, Corporate, Excellence in Healthcare Partnerships Awards, NHS ConfedExpo, PMGroup, Visions4Health
PMGroup Worldwide and Visions4Health have launched the Excellence in Healthcare Partnerships (EHP) Awards to recognise collaborations that deliver measurable benefits …
CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany
June 26, 2025Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access
CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …
FDA grants orphan drug designation to antibody-mediated rejection treatment
June 26, 2025Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation
Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …
Oxeltis secures €800,000 grant to advance antiviral candidate for emerging tropical viruses
June 26, 2025Medical Communications, Research and Development Corporate, Defense Innovation Agency, National Research Agency, Oxeltis, RNA viruses, Virology, contract research organisation
Oxeltis, a French contract research organisation specialising in medicinal and organic chemistry, has announced that it will lead the BUNYANTIVIR …
Roche candidate shows early promise for treating haemophilia A
June 25, 2025Research and Development Chugai, Haematology, Roche, clinical trial, haemophilia a, prophylactic therapy
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …
Novo Nordisk’s therapy delivers significant weight loss in trial
June 25, 2025Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions
Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …
Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn
June 25, 2025Research and Development CEO, Nephrology, Opterion Health, board of directors, cfo, chronic kidney disease, dialysis solution
Swiss life sciences company Opterion Health has appointed two senior industry figures to its board of directors: Rice Powell, former …
PLL Therapeutics appoints renowned ALS expert Philippe Corcia to scientific board
June 25, 2025Research and Development ALS Reference Centre, National ALS Motor Neuron Study Group, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis (ALS), scientific board
PLL Therapeutics has appointed leading amyotrophic lateral sclerosis (ALS) researcher Philippe Corcia to its scientific board, marking a strategic move …
NHS ConfedExpo 2025: a platform for change in UK health and care
June 24, 2025Medical Communications Accenture, AstraZeneca, Corporate, Excellence in healthcare Partnership (EHP) Awards, Manchester, NHS ConfedExpo, NHS Confederation, NHS England, Novartis UK, Visions4Health
This year’s NHS ConfedExpo took place on 11 to 12 June at Manchester Central, bringing together around 9,000 attendees. Among …
Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
June 24, 2025Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …
Neurizon confirms positive results for prospective ALS treatment
June 23, 2025Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases
Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …
AOTI achieves broad market access in Germany for diabetic foot ulcer therapy
June 23, 2025Market Access, Medical Communications, Sales and Marketing AOTI, Diabetes, European pharma market, German pharma market, Wound Healing, diabetic foot ulcers, market access, positive recommendation
AOTI, focused on solutions for severe and chronic wounds, has announced that its unique topical wound oxygen (TWO2) therapy has …
Novo Nordisk presents promising findings for haemophilia treatment
June 23, 2025Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval
Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …
Terumo BCT showcases new CAR-T workflow enabling faster cell expansion
June 20, 2025Manufacturing and Production CAR-T cell manufacturing, Devices, EULV, Eureka Biotechnology, Terumo Blood and Cell Technologies, cell therapy, eureka, gene therapy
Terumo Blood and Cell Technologies (Terumo BCT) has unveiled a new automated workflow that consolidates three critical CAR-T manufacturing steps …
NICE recommends spevigo for rare and severe psoriasis flares
June 20, 2025Medical Communications, Research and Development Dermatology, NHS, National Institute for Health and Care Excellence, generalised pustular psoriasis
The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the treatment of generalised pustular psoriasis …
Latest content
FibroFind appoints Lee Borthwick as CEO
